Ethics bureaucracy: a significant hurdle for collaborative follow-up of drug effectiveness in rare childhood diseases
Arch Dis Child
.
2012 Jun;97(6):561-3.
doi: 10.1136/archdischild-2011-301175.
Epub 2012 Feb 22.
Authors
Mats G Hansson
,
Marco Gattorno
,
Joanna Stjernschantz Forsberg
,
Nils Feltelius
,
Alberto Martini
,
Nicolino Ruperto
PMID:
22362719
DOI:
10.1136/archdischild-2011-301175
No abstract available
Publication types
Editorial
Research Support, Non-U.S. Gov't
MeSH terms
Child
Clinical Trials as Topic / ethics*
Ethics, Medical
Europe
Humans
Pediatrics / ethics*
Rare Diseases / drug therapy*
Registries*